Which Pre-CAR-T chemo is safer? new trial aims to find out
NCT ID NCT07593482
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether bendamustine causes fewer severe side effects than the standard fludarabine/cyclophosphamide combination when given before CAR-T cell therapy for B-cell lymphoma. About 92 people will be randomly assigned to one of the two chemotherapy regimens. The main goal is to see which approach leads to fewer serious complications like cytokine release syndrome, fever with low white blood cell counts, and nerve-related side effects within the first month after CAR-T infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bendamustine hydrochloride, cyclophosphamide, fludarabine
- What this could lead to
- If bendamustine works better, it could become the standard pre-CAR-T chemotherapy, reducing severe side effects like cytokine release syndrome and infections.
- What could go wrong
- This is a small, early-phase trial (92 people) comparing two already-used drugs, so it may not show a clear winner. Side effects from both regimens are still possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ente Ospedaliero Cantonale (EOC)-Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, 6500, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
HOCH Health Ostschweiz - Kantonsspital St. Gallen
Sankt Gallen, 9007, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Inselspital Bern - Universitätsklinik für Medizinische Onkologie
Bern, 3010, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Aarau
Aarau, 5001, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kantonsspital Graubünden
Chur, 7000, Switzerland
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Klinik für Hämatologie und Onkologie Hirslanden Zürich
Zurich, 8032, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Les hôpitaux universitaires de Genève
Geneva, 1211, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Luzerner Kantonsspital
Lucerne, 6004, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Universitätsspital Basel
Basel, 4056, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope
- New drug combo aims to tame aggressive lymphoma in frail patients
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Double-Pronged immune cells take aim at stubborn blood cancers
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers